Apitoria Pharma Private Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is RIVAROXABAN, with a corresponding US DMF Number 29048.
Remarkably, this DMF maintains an Active status since its submission on February 05, 2015, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of April 15, 2015, and payment made on February 02, 2015, indicating their dedication to facilitating drug approvals, Categorized as Type II